Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$55.63 USD

55.63
5,356,452

-20.14 (-26.58%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $55.55 -0.08 (-0.14%) 6:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (156 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Orthofix (OFIX) Progresses With Limb-Lengthening Device

by Zacks Equity Research

Orthofix's (OFIX) Fitbone TAA intramedullary limb-lengthening system is implanted through a minimally invasive procedure.

Zacks Equity Research

Abbott (ABT) Reveals Favorable Data on Tricuspid Regurgitation

by Zacks Equity Research

Abbott Laboratories (ABT) demonstrates the superiority of the TriClip device in treating patients with severe, symptomatic tricuspid regurgitation.

Zacks Equity Research

Here's Why You Should Add Stryker (SYK) Stock to Your Portfolio

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on it.

Zacks Equity Research

Here's Why Investors Should Buy Zimmer Biomet (ZBH) Now

by Zacks Equity Research

Investors are optimistic about Zimmer Biomet (ZBH) on ongoing business recovery.

Zacks Equity Research

Alcon (ALC) Unveils Expansive Vision Care Products at SECO 2023

by Zacks Equity Research

Alcon (ALC) showcases its reusable toric lens and dry eye/ocular health offerings at the SECO International Meeting 2023 in Atlanta.

Zacks Equity Research

Myriad Genetics' (MYGN) New Pact to Extend HRD Testing Access

by Zacks Equity Research

Myriad Genetics (MYGN), together with Illumina, will seek joint HRD companion diagnostics partnerships with pharmaceutical companies globally.

Zacks Equity Research

Zimmer Biomet (ZBH) Gains From Market Recovery, Global Growth

by Zacks Equity Research

Zimmer Biomet (ZBH) witnesses continued traction across hip products, including the G7 revision system and Avenir Complete primary hip.

Zacks Equity Research

Haemonetics (HAE) Autotransfusion System Gets 510(k) Clearance

by Zacks Equity Research

The latest development is expected to upgrade Haemonetics' (HAE) Cell Salvage platform and broaden the company's scope in the growing autotransfusion space.

Zacks Equity Research

Neogen's (NEOG) New Launches Aid, Margin Pressure Stays

by Zacks Equity Research

Neogen (NEOG) continues to see rising revenues from the Food Safety business.

Zacks Equity Research

Here's Why You Should Invest in Hologic (HOLX) Stock Now

by Zacks Equity Research

Investors are optimistic about Hologic (HOLX) on the continued strength of GYN Surgical and Breast Health businesses.

Zacks Equity Research

Hologic's (HOLX) Strategic Buyouts Aid, Surgical Arm Grows

by Zacks Equity Research

Hologic's (HOLX) GYN Surgical results underscore a more diverse surgical business with more growth drivers than in the past.

Zacks Equity Research

Here's Why You Should Hold on to Align Technology (ALGN) Now

by Zacks Equity Research

Investors are optimistic about Align Technology (ALGN) on the growing market adoption of the iTero Element 5D Plus imaging system.

Zacks Equity Research

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

by Zacks Equity Research

Investors are optimistic about IDEXX's (IDXX) strong global performance.

Zacks Equity Research

Medtronic's (MDT) MiniMed 780G System Shows Favorable Results

by Zacks Equity Research

Medtronic's (MDT) MiniMed 780G system was designed to forecast real-life requirements where carbohydrate counts aren't always exact and meal doses are often missed.

Zacks Equity Research

Agios (AGIO) Q4 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Agios (AGIO) reports mixed fourth-quarter results as earnings beat estimates and revenues miss the same.

Kevin Cook headshot

Bull of the Day: Haemonetics (HAE)

by Kevin Cook

Leader in blood management for hospitals see estimates and price targets rise after strong quarter

Zacks Equity Research

New Strong Buy Stocks for February 10th

by Zacks Equity Research

SNEX, DTEGY, CLVT, HAE and ARCC have been added to the Zacks Rank #1 (Strong Buy) List on February 10, 2022.

Zacks Equity Research

Zacks Industry Outlook Highlights Stryker, Zimmer Biomet and Haemonetics

by Zacks Equity Research

Stryker, Zimmer Biomet and Haemonetics have been highlighted in this Industry Outlook article.

Zacks Equity Research

Why Haemonetics (HAE) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Haemonetics (HAE) Q3 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

In the fiscal third quarter, Haemonetics (HAE) incurs higher research and development costs, primarily due to increased investments in product innovation.

Indrajit Bandyopadhyay headshot

3 Medical Products Stocks Navigating Industry Challenges

by Indrajit Bandyopadhyay

Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. SYK, ZBH and HAE are well-poised to gain from the favorable factors.

Zacks Equity Research

Exact Sciences (EXAS) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Continued increase in Cologuard volume is likely to have benefited Exact Sciences (EXAS) Q4 performance.

Zacks Equity Research

Haemonetics (HAE) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Haemonetics (HAE) delivered earnings and revenue surprises of 7.59% and 4.41%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Molina (MOH) to Post Q4 Earnings: What You Should Expect

by Zacks Equity Research

Molina Healthcare's (MOH) fourth-quarter results are likely to reflect growth in premiums and Investment income.

Zacks Equity Research

Can Lower Managed Care Profits Hurt Centene (CNC) Q4 Earnings?

by Zacks Equity Research

Centene's (CNC) fourth-quarter results are likely to reflect growth in premiums and memberships.